Literature DB >> 10523037

Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors.

K Lidhar1, M Korbonits, S Jordan, Z Khalimova, G Kaltsas, X Lu, R N Clayton, P J Jenkins, J P Monson, G M Besser, D G Lowe, A B Grossman.   

Abstract

The cell cycle is regulated by a number of inhibitors, including p27Kip1 (p27), which belongs to the kip1 family. By binding to the cyclin/cyclin-dependent kinase complexes, it regulates progression of G1 to S phase in the cell cycle. It has been reported that p27 knockout mice develop multiorgan hyperplasia and intermediate lobe pituitary tumors secreting ACTH. Previously, we and others have been unable to show any consistent change in messenger RNA expression or genomic mutations for p27 in human corticotroph adenomas. However, dysregulation at the protein level has been reported in nonendocrine tumors, and we, therefore, investigated the expression of p27 in a range of benign and metastatic pituitary tumors. We studied a total of 107 pituitaries, including normal pituitary (n = 20), Cushing's disease (n = 21), acromegaly (n = 19), nonfunctioning adenomas (n = 18), prolactinomas (n = 7), TSH-omas (n = 2), FSH-omas (n = 6), aggressive tumors showing invasiveness and recurrence (n = 9), and metastatic pituitary carcinomas (n = 5). Using standard immunohistochemical techniques with a highly specific monoclonal antibody, p27 expression was determined quantitatively as the percentage of cells showing strongly positive, weak, or negative staining. In each sample, approximately 500 cells were analyzed. We also analyzed normal pituitaries using double-labeling for p27 and each of the pituitary hormones to characterize the expression of p27 in each cell type. p27 was expressed in normal pituitary cells; in tumors expressing GH, prolactin, TSH, and FSH; and in aggressive tumors, but markedly reduced expression of p27 was seen in corticotroph tumors and pituitary carcinomas. In the normal pituitary, somatotroph, lactotroph, and thyrotroph cells showed strong p27 staining, whereas normal corticotroph cells showed a much lower level of p27 staining (P < 0.001). Somatotroph, lactotroph, gonadotroph, and thyrotroph adenomas showed a lower level of p27 expression compared with normal somatotrophs (P = 0.02), lactotrophs (P = 0.03), gonadotrophs (P = 0.01), and thyrotrophs, respectively, whereas the lower level of p27 expression present in normal corticotrophs virtually disappeared in corticotroph adenomas (P = 0.001). We conclude that pituitary adenomas show a lower level of p27 protein expression than the normal cells from which they are derived, with malignant transformation leading to complete loss of p27 immunoreactivity. Corticotrophs are quite different to other pituitary cell types in terms of p27 immunoreactivity because both normal and tumorous corticotrophs have low p27 staining, and we speculate that this may relate to their inherent control mechanisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10523037     DOI: 10.1210/jcem.84.10.6066

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors.

Authors:  Madalina Musat; Márta Korbonits; Megan Pyle; Maria Gueorguiev; Blerina Kola; Damian G Morris; Michael Powell; Constantin Dumitrache; Catalina Poiana; Ashley B Grossman
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

2.  p19Ink4d is a tumor suppressor and controls pituitary anterior lobe cell proliferation.

Authors:  Feng Bai; Ho Lam Chan; Matthew D Smith; Hiroaki Kiyokawa; Xin-Hai Pei
Journal:  Mol Cell Biol       Date:  2014-03-31       Impact factor: 4.272

Review 3.  Familial pituitary tumor syndromes.

Authors:  Marianne S Elston; Kerrie L McDonald; Roderick J Clifton-Bligh; Bruce G Robinson
Journal:  Nat Rev Endocrinol       Date:  2009-06-30       Impact factor: 43.330

4.  Cyclins D1 and D3 and topoisomerase II alpha in inactive pituitary adenomas.

Authors:  W Saeger; S Schreiber; D K Lüdecke
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

5.  EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.

Authors:  Hidenori Fukuoka; Odelia Cooper; Anat Ben-Shlomo; Adam Mamelak; Song-Guang Ren; Dave Bruyette; Shlomo Melmed
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

6.  Immunohistochemical analysis of p27 (Kip1) in human pituitary glands and in various types of pituitary adenomas.

Authors:  K Komatsubara; S Tahara; K Umeoka; N Sanno; A Teramoto; R Y Osamura
Journal:  Endocr Pathol       Date:  2001       Impact factor: 3.943

7.  Deletion of Men1 and somatostatin induces hypergastrinemia and gastric carcinoids.

Authors:  Sinju Sundaresan; Anthony J Kang; Michael M Hayes; Eun-Young K Choi; Juanita L Merchant
Journal:  Gut       Date:  2016-02-09       Impact factor: 23.059

Review 8.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

Review 9.  The molecular biology of pituitary tumors: a personal perspective.

Authors:  Ashley B Grossman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

10.  Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells.

Authors:  Xuegong Zhu; Katie Lee; Sylvia L Asa; Shereen Ezzat
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.